Harpoon Therapeutics, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
611 Gateway Boulevard, Suite 400, South San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2023 - Nov 9, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 144 % -20.6%
Debt-to-equity 1.85K % +683%
Return On Equity -895 % -351%
Return On Assets -46 % +22.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16.9M shares -49%
Common Stock, Shares, Outstanding 4.11M shares -87.6%
Entity Public Float 26.8M USD -89.8%
Common Stock, Value, Issued 1K USD -75%
Weighted Average Number of Shares Outstanding, Basic 3.95M shares +19.4%
Weighted Average Number of Shares Outstanding, Diluted 3.95M shares +19.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 37.3M USD +16.1%
Research and Development Expense 58.6M USD -29.5%
General and Administrative Expense 16.1M USD -20.3%
Operating Income (Loss) -39.1M USD +45%
Net Income (Loss) Attributable to Parent -30.5M USD +57%
Earnings Per Share, Basic 1.89 USD/shares +86.9%
Earnings Per Share, Diluted 1.89 USD/shares +86.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.7M USD -64.8%
Marketable Securities, Current 13.9M USD -11.8%
Cash, Cash Equivalents, and Short-term Investments 31.6M USD -52.2%
Assets, Current 34.3M USD -50.4%
Property, Plant and Equipment, Net 3.53M USD -55.5%
Operating Lease, Right-of-Use Asset 8.86M USD +57.6%
Other Assets, Noncurrent 898K USD +10.7%
Assets 47.6M USD -43%
Accounts Payable, Current 3.44M USD +30.1%
Employee-related Liabilities, Current 2.68M USD -32%
Accrued Liabilities, Current 11.7M USD -25.2%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 18.1M USD -66.5%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 11.5M USD +26.1%
Liabilities 43M USD -35.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1K USD
Retained Earnings (Accumulated Deficit) -365M USD -9.13%
Stockholders' Equity Attributable to Parent 4.54M USD -73.1%
Liabilities and Equity 47.6M USD -43%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -19.3M USD +23.6%
Net Cash Provided by (Used in) Financing Activities 26.6M USD +3107%
Net Cash Provided by (Used in) Investing Activities 2.44M USD -92%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 4.11M shares -87.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 17.9M USD -64.8%
Deferred Tax Assets, Valuation Allowance 73.9M USD +16.5%
Deferred Tax Assets, Gross 76.2M USD +17.7%
Operating Lease, Liability 14.5M USD +32.2%
Payments to Acquire Property, Plant, and Equipment 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -30.5M USD +57%
Lessee, Operating Lease, Liability, to be Paid 18M USD +33.9%
Property, Plant and Equipment, Gross 3.85M USD -75.6%
Operating Lease, Liability, Current 2.97M USD +62.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.35M USD +54%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.23M USD +54.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.47M USD +41.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.49M USD +54.1%
Deferred Tax Assets, Operating Loss Carryforwards 50.9M USD +9.97%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 20.8M USD +37.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.79M USD -7.44%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 662K USD +9.6%
Deferred Tax Assets, Net of Valuation Allowance 2.28M USD +76%
Share-based Payment Arrangement, Expense 5.49M USD -46.9%
Interest Expense 2.05M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%